Dr. Choueiri on Savolitinib in Papillary Renal Cell Cancer

Toni Choueiri, MD
Published: Thursday, Apr 13, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer (PRCC).

In the largest PRCC trial to date, savolitinib, a specific MET-only inhbitor, was evaluated in this patient population. Although little is known about the biology of PRCC, says Choueiri, a subset of patients harbor an alteration in the MET gene—MET mutation, MET amplificiation, and others.

Savolitinib was generally well tolerated in MET-driven patients, but further clinical investigation is warrented, says Choueiri.
 


Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer (PRCC).

In the largest PRCC trial to date, savolitinib, a specific MET-only inhbitor, was evaluated in this patient population. Although little is known about the biology of PRCC, says Choueiri, a subset of patients harbor an alteration in the MET gene—MET mutation, MET amplificiation, and others.

Savolitinib was generally well tolerated in MET-driven patients, but further clinical investigation is warrented, says Choueiri.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x